Serum Gastrin-17 Fasting Test in Lahore at Chughtai Lab

Serum Gastrin-17 (Fasting) at Chughtai Lab

Serum Gastrin-17 (Fasting) is a highly specialized serological biomarker test used to evaluate the functional and structural integrity of the stomach mucosa, specifically the antrum. Gastrin-17 (G-17) is a peptide hormone synthesized, stored, and secreted exclusively by the specialized G-cells located in the antrum of the stomach. It plays a pivotal role in gastrointestinal physiology by regulating gastric acid secretion from the parietal cells of the gastric corpus (body) and stimulating the growth of the gastric mucosa. Under normal physiological conditions, a feedback mechanism exists between gastric acidity and gastrin secretion: low pH (high acidity) in the stomach inhibits gastrin release, while high pH (low acidity) stimulates it. Measuring the fasting levels of Gastrin-17 provides invaluable clinical insights into the state of the gastric mucosa without the immediate necessity of invasive endoscopic procedures.

At Chughtai Lab, a premier diagnostic network in Lahore and across Pakistan, this test is performed using advanced automated immunoassay technology. The clinical importance of the fasting Gastrin-17 test lies in its ability to act as a non-invasive “serological biopsy.” When combined with other biomarkers like Pepsinogen I, Pepsinogen II, and Helicobacter pylori antibodies (collectively known as a GastroPanel), Gastrin-17 helps clinicians differentiate between healthy gastric mucosa, antrum-specific atrophic gastritis, corpus-specific atrophic gastritis, and pan-atrophic gastritis. This diagnostic value is crucial because mucosal atrophy is a well-established pre-cancerous state. Early identification of these changes allows for timely intervention, personalized treatment plans, and structured surveillance strategies, significantly reducing the risk of gastric adenocarcinoma.

The benefits of opting for a Serum Gastrin-17 (Fasting) test at Chughtai Lab include its non-invasive nature, high specificity for antral function, and the precision of modern laboratory diagnostics. Common clinical indications for this test include chronic dyspepsia, suspected Helicobacter pylori infection, screening for gastric cancer risk in high-risk populations, monitoring patients on long-term acid-suppressive therapy (such as proton pump inhibitors), and evaluating patients with suspected autoimmune atrophic gastritis or pernicious anemia.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the utmost accuracy and clinical validity of the Serum Gastrin-17 (Fasting) test results, patients must adhere strictly to the following preparation guidelines:

• Strict Fasting: The patient must fast for a minimum of 10 to 12 hours before the blood sample collection. Only plain water is permitted during this fasting period. Avoid tea, coffee, juices, sodas, and all forms of solid food.
• Medication Management: Certain medications significantly alter gastric acid secretion and gastrin levels. Under the explicit guidance of the prescribing physician, patients may need to discontinue Proton Pump Inhibitors (PPIs) like omeprazole, esomeprazole, or lansoprazole for at least 1 to 2 weeks prior to the test. H2-receptor antagonists (such as ranitidine or famotidine) and antacids may need to be avoided for 24 to 48 hours before sample collection.
• Avoid Alcohol and Nicotine: Patients should refrain from consuming alcohol and smoking for at least 24 hours before the test, as these substances can stimulate gastric secretions and alter baseline hormone levels.
• Stress Reduction: Physical and emotional stress can influence gastrointestinal hormones. Patients are advised to remain calm and rested before the blood draw.

During the Procedure

The collection of the blood sample for the Serum Gastrin-17 (Fasting) test at Chughtai Lab follows standard, stringent clinical protocols to maintain sample integrity and patient comfort:

• Patient Positioning: The patient is asked to sit comfortably in a specialized phlebotomy chair or lie down if they feel lightheaded.
• Sanitization: The phlebotomist identifies a suitable vein, typically the median cubital vein in the antecubital fossa of the arm, and thoroughly cleanses the area with an antiseptic swab.
• Venipuncture: A sterile, single-use needle is inserted into the vein to collect a venous blood sample. The blood is drawn into a specific gel-barrier tube (serum separator tube) or as designated by the laboratory protocol.
• Duration: The entire venipuncture process is highly efficient, typically taking less than five minutes.
• Post-Collection Care: Once the needle is withdrawn, gentle pressure is applied to the puncture site with a sterile cotton ball, followed by the application of a bandage to prevent bruising.
• Safety and Comfort: The procedure is safe, with minimal discomfort akin to a brief pinch. Chughtai Lab adheres to strict biosafety standards, ensuring all equipment is sterile and disposable.

When is a Serum Gastrin-17 (Fasting) Performed?

Evaluation of Atrophic Gastritis

Atrophic gastritis is a chronic inflammatory condition characterized by the progressive loss of gastric glandular structures. When inflammation affects the antrum, G-cells are destroyed, leading to abnormally low fasting levels of Gastrin-17. Conversely, if the atrophy is confined to the corpus (body) of the stomach, the loss of acid-producing parietal cells leads to achlorhydria. The lack of acid removes the inhibitory feedback on the antrum, causing G-cells to hyper-secrete Gastrin-17, resulting in highly elevated fasting levels. Physicians request this test to non-invasively locate and assess the severity of mucosal atrophy.

Assessment of Helicobacter pylori Infection

Helicobacter pylori is a major etiological factor in chronic gastritis, peptic ulcer disease, and gastric cancer. An active H. pylori infection in the antrum can cause localized inflammation that alters G-cell function. In the early stages or in non-atrophic H. pylori gastritis, fasting Gastrin-17 levels may rise due to inflammatory stimulation. However, if the infection leads to severe antral atrophic gastritis over time, Gastrin-17 levels drop significantly. This test helps clinicians understand the functional impact of the infection on the gastric mucosa.

Investigation of Gastroesophageal Reflux Disease (GERD) and Dyspepsia

Patients presenting with chronic, unexplained dyspepsia, bloating, early satiety, or severe acid reflux often undergo this test to rule out organic mucosal diseases. While functional dyspepsia may show normal Gastrin-17 levels, abnormal levels point toward structural mucosal damage or severe acid secretory dysfunction. This differentiation is vital for formulating an effective, targeted therapeutic strategy rather than relying on empirical acid suppression.

Screening for Gastric Cancer Risk

Gastric cancer often develops through a cascade of mucosal changes starting from chronic gastritis, progressing to atrophic gastritis, intestinal metaplasia, dysplasia, and finally adenocarcinoma. Low fasting levels of Gastrin-17, especially when accompanied by low Pepsinogen I levels, serve as a strong serological indicator of advanced gastric atrophy, which is a high-risk state for gastric cancer. Identifying these high-risk patients allows gastroenterologists to schedule targeted screening endoscopies.

Diagnosis of Gastric Acid Secretion Disorders

Fasting Gastrin-17 is an essential tool in evaluating states of abnormal gastric acid secretion. In patients with unexplained hyperacidity or severe peptic ulcers, measuring Gastrin-17 helps distinguish between normal physiological feedback and pathological conditions. For instance, extremely high gastrin levels can point toward gastrin-producing tumors (gastrinomas) or G-cell hyperplasia, guiding the clinical team toward advanced imaging and specialized management.

What Does a Serum Gastrin-17 (Fasting) Detect?

The Serum Gastrin-17 (Fasting) test is highly sensitive to the functional state of the gastric antrum and the overall acid-base balance of the stomach. It can detect, indicate, or assist in the diagnosis of the following clinical findings and conditions:

• Antral mucosal atrophy (indicated by abnormally low fasting G-17 levels)
• Corpus-limited atrophic gastritis (indicated by elevated fasting G-17 levels due to low acid feedback)
• Healthy, normally functioning gastric antrum (indicated by normal baseline G-17 levels)
• Achlorhydria or severe hypochlorhydria (profound lack of stomach acid)
• Hyperchlorhydria (excessive stomach acid suppressing G-17 release)
• Helicobacter pylori-associated antral gastritis
• Autoimmune atrophic gastritis (pernicious anemia)
• Gastric antral G-cell hyperplasia
• Zollinger-Ellison Syndrome (extremely elevated gastrin, though total gastrin is primary, G-17 is highly elevated)
• Risk of gastric adenocarcinoma associated with mucosal atrophy
• Risk of gastric neuroendocrine tumors (carcinoids) secondary to hypergastrinemia
• Physiological response to prolonged, high-dose Proton Pump Inhibitor (PPI) therapy
• Recovery of antral mucosa following successful Helicobacter pylori eradication
• Gastric stump atrophy in patients who have undergone partial gastrectomy
• Functional dyspepsia (where mucosal markers typically remain within normal limits)
• Barrett’s esophagus associated with altered gastric secretory dynamics
• Malabsorption of essential nutrients (like Vitamin B12, iron, and calcium) secondary to hypoacidic states
• Peptic ulcer disease localization and underlying pathophysiology
• Antral G-cell hypoplasia or dysfunction (rare congenital or acquired states)
• Hypoacidity associated with aging (senile gastric mucosal atrophy)

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is widely recognized for its state-of-the-art diagnostic infrastructure and its commitment to providing rapid, highly accurate results. For specialized serological assays like the Serum Gastrin-17 (Fasting) test, the laboratory utilizes advanced automated platforms that minimize human error and optimize processing times. Typically, the test reports are processed and verified by consultant pathologists within 24 to 48 hours of sample collection.

Patients can access their diagnostic reports seamlessly through multiple digital channels provided by Chughtai Lab. Reports can be downloaded directly from the official Chughtai Lab website by entering the patient’s case number and access code. Additionally, the Chughtai Lab Mobile App, available on both iOS and Android platforms, offers a user-friendly interface where patients can view, download, and archive their entire medical report history. For further convenience, Chughtai Lab also offers automated report delivery via WhatsApp and email, ensuring that patients and their consulting physicians receive critical diagnostic data without delay.

Serum Gastrin-17 (Fasting) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Fasting Gastrin-17 Level	Within established reference range (typically 1.0 – 7.0 pmol/L, subject to lab standards)	Low: < 1.0 pmol/L (Antral atrophy or high acid) High: > 7.0 pmol/L (Corpus atrophy, PPI use, or G-cell hyperplasia)
Antral Mucosa Integrity	Normal, healthy G-cell population with active hormone synthesis	Antral mucosal atrophy, G-cell loss, or localized H. pylori-induced tissue damage
Corpus Mucosa Status	Healthy parietal cells producing normal physiological levels of hydrochloric acid	Corpus atrophy, loss of parietal cells, leading to compensatory G-cell hypersecretion
Gastric Acid Secretion	Balanced hydrochloric acid production maintaining normal gastric pH	Achlorhydria/Hypochlorhydria: Low acid triggering high G-17 Hyperchlorhydria: High acid suppressing G-17
Helicobacter pylori Impact	No active infection; normal mucosal response	Active antral infection causing mucosal inflammation, or chronic infection leading to mucosal scarring
Atrophic Gastritis Type	No evidence of chronic atrophic changes	Type A (Autoimmune): High G-17 due to corpus atrophy Type B (Environmental/H. pylori): Low G-17 if antrum is severely affected
Gastric Malignancy Risk	Low, baseline risk associated with healthy gastric tissue	Elevated risk of gastric adenocarcinoma or neuroendocrine tumors associated with severe mucosal atrophy

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Serum Gastrin-17 (Fasting)?

• Accredited Diagnostic Network: Chughtai Lab is one of Pakistan’s most trusted and widely accredited diagnostic networks, ensuring international standards of quality.
• Advanced Automated Technology: The laboratory utilizes cutting-edge immunoassay analyzers to deliver highly precise and reproducible Gastrin-17 measurements.
• Expert Pathological Supervision: All specialized gastroenterology and serology reports are reviewed and signed off by highly qualified consultant pathologists.
• Convenient Home Sample Collection: Patients can avail themselves of Chughtai Lab’s professional home sampling services, bringing clinical excellence to their doorstep.
• Seamless Digital Access: Reports are easily accessible online via the official website, the dedicated Chughtai Lab Mobile App, and WhatsApp.
• Strict Quality Control: The lab participates in rigorous internal and external quality assurance programs to maintain the highest level of diagnostic accuracy.
• Comprehensive Test Panels: Chughtai Lab offers complete gastric health assessments, allowing Gastrin-17 to be co-tested with Pepsinogens and H. pylori antibodies for a complete GastroPanel.
• Patient-Centric Care: With a vast network of collection centers and 24/7 services in major hubs, Chughtai Lab prioritizes patient comfort, convenience, and timely care.